Union Health Minister to Launch Tetanus and Adult Diphtheria (Td) Vaccine at Central Research Institute, Kasauli on 21st February 2026

1. At a Glance

• Td (Tetanus and adult Diphtheria) vaccine is an adsorbed, reduced D-antigen content vaccine providing dual protection against tetanus + diphtheria, set to replace the monovalent TT (Tetanus Toxoid) vaccine in India's Universal Immunization Programme (UIP) [S1][S2].
• Launched by Union Health Minister J.P. Nadda on 21 February 2026 at the Central Research Institute (CRI), Kasauli, Himachal Pradesh — India's first indigenously manufactured Td vaccine by a government PSU [S1][S2].
• Aligns India with the WHO 2006 recommendation for transition from TT to Td; addresses waning diphtheria immunity in adolescents/adults [S1].
• Relevant for GS-II (Health/Govt schemes) and GS-III (Sci-Tech, indigenous biotech).

2. Why in the News

• 20–21 Feb 2026: PIB announced launch of indigenous Td vaccine at CRI Kasauli by Union Health Minister [S1][S2].
• NTAGI (National Technical Advisory Group on Immunization) recommended TT→Td replacement for all age groups including pregnant women [S1].
• CRI to supply ~55 lakh doses of Td to UIP by April 2026 [S2].

3. Background & Evolution

• 1905: CRI Kasauli established under Directorate General of Health Services, MoHFW [S2].
• 1978: Expanded Programme on Immunization (EPI) launched in India; renamed UIP in 1985.
• 2006: WHO recommended global transition from TT → Td vaccine due to declining adult diphtheria antibody levels [S1].
• 2017: WHO Tetanus Vaccine Position Paper reaffirmed Td use [S1].
• 2026: India operationalises transition with indigenous Td production at CRI [S1][S2].

4. Core Static Facts

• Vaccine: Td = Tetanus + adult Diphtheria (Adsorbed, Reduced D-antigen) [S1].
• Manufacturer: Central Research Institute (CRI), Kasauli, Himachal Pradesh [S1][S2].
• Parent body: Directorate General of Health Services, Ministry of Health and Family Welfare [S2].
• Launch date: 21 February 2026 by Shri J.P. Nadda [S1].
• Initial supply commitment: ~55 lakh doses to UIP by April 2026 [S2].
• Recommending body (India): NTAGI [S2].
• Recommending body (global): WHO (2006 recommendation; reaffirmed in Tetanus Vaccine Position Paper) [S1].
• Three central govt vaccine PSUs: CRI Kasauli; Pasteur Institute of India (PII), Coonoor; BCG Vaccine Laboratory (BCGVL), Guindy [S2].
• CRI is first central govt institute with cGMP-compliant DPT facility and now licensed for Td production [S2].

5. Multi-Dimensional Analysis

Scientific / Technological - Reduced "d" (lowercase) antigen content avoids hyper-reactogenicity in adults vs paediatric "D" dose [S1]. - Indigenisation through CRI reduces import dependency; cGMP compliance signals regulatory upgrade [S2].

Social / Public Health - Targets booster gap in adolescents, adults, pregnant women; sustains Maternal & Neonatal Tetanus Elimination (MNTE) status India achieved in 2015 [S1]. - Extends protection to diphtheria — antibody titres wane post-childhood DPT [S1].

Administrative / Governance - Revitalisation of dormant public sector vaccine units (CRI, PII, BCGVL were de-licensed in 2008, restored 2010 onwards) demonstrates Atmanirbhar Bharat in biologics [S2]. - Federal: Centre supplies vaccines free to States under UIP.

Economic - Domestic production lowers procurement costs for UIP (one of world's largest immunization programmes — ~2.6 crore newborns, ~2.9 crore pregnant women annually).

6. Recent Developments

• 20 Feb 2026: PIB advance press release on Td vaccine launch [S1].
• 21 Feb 2026: Formal launch at CRI Kasauli by Union Health Minister [S2].
• By April 2026: 55 lakh doses to be supplied to UIP [S2].
• NTAGI recommendation: TT→Td transition across all age cohorts including pregnant women [S2].

7. Prelims Hooks

• Td vaccine launched at CRI Kasauli, Himachal Pradesh on 21 Feb 2026 [S1].
• "d" in Td = reduced-dose diphtheria toxoid (vs paediatric DPT's full-strength D) [S1].
• WHO recommended TT→Td transition in 2006 [S1].
• Recommending Indian body: NTAGI, under MoHFW [S2].
• CRI Kasauli established in 1905 under DGHS [S2].
• Three MoHFW vaccine institutes: CRI Kasauli, PII Coonoor, BCGVL Guindy [S2].
• CRI is first central govt institute with cGMP-compliant DPT facility [S2].
• Initial supply to UIP: 55 lakh doses by April 2026 [S2].
• UIP launched in India in 1985 (predecessor EPI: 1978).
• Td replaces monovalent Tetanus Toxoid (TT) vaccine [S1].

8. Mains Relevance

• GS-II: Issues relating to development & management of Social Sector/Services (Health); Government policies & interventions.
• GS-III: Science & Technology — indigenisation, biotech, achievements of Indians in S&T.
• Likely question stems: 1. "Discuss the rationale and public-health significance of replacing TT with Td vaccine in India's UIP." 2. "Indigenous vaccine manufacturing by public-sector institutes is critical for India's health security. Examine in light of recent developments at CRI Kasauli." 3. "Examine the role of NTAGI in shaping India's immunization policy."

9. Related Topics to Study Next

• Universal Immunization Programme (UIP) — parent scheme.
• Mission Indradhanush / Intensified Mission Indradhanush 5.0 — coverage expansion.
• U-WIN portal — digital immunization tracking.
• NTAGI — apex advisory body composition & mandate.
• Maternal & Neonatal Tetanus Elimination (2015) — India's WHO certification.
• Pasteur Institute, Coonoor & BCGVL Guindy — sister PSUs.
• National Vaccine Policy 2011 — overarching framework.
• WHO Position Papers on vaccines — global standard-setting mechanism.

10. Common Errors / Trap Areas

• Td ≠ Tdap: Td contains tetanus + diphtheria only; Tdap adds acellular pertussis.
• CRI is in Himachal Pradesh (Kasauli), NOT Uttarakhand or Punjab.
• Td replaces TT (Tetanus Toxoid) — not DPT, which continues for children.
• WHO recommendation year is 2006, not 2017 (which is the reaffirmation).
• CRI is under MoHFW/DGHS, not under ICMR or DBT.

11. Sources

• [S1] Union Health Minister to Launch Tetanus and Adult Diphtheria (Td) Vaccine at CRI Kasauli on 21st February 2026 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2230793 — (tier: 1)
• [S2] Union Health Minister Shri J.P. Nadda Launches Indigenously Manufactured Td Vaccine at CRI, Himachal Pradesh — https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2231147 — (tier: 1)